All In Biotech

Drug Trial Radar · NCT06310551

First Time in Human Study of Long Acting VH4524184 Formulations

A Phase 1 Double-Blind (Sponsor-unblinded), Placebo-Controlled Randomized, Single Ascending Dose and Multiple Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Parenterally Administered VH4524184 in Healthy Adults

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 348 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

348

Planned (sponsor's estimate)

Start

Mar 21, 2024

Primary completion

May 28, 2029

Study completion Jun 29, 2029

Sponsor

Lead sponsor
ViiV HealthcareGSK (GSK)
Sponsor type
Industry
First posted
Mar 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to identify 1 or more doses of parenterally administered VH4524184 that are safe, well tolerated and yield a PK drug exposure profile necessary to deliver a long-acting antiretroviral therapy for the treatment of HIV-1 infection.

Conditions

  • HIV Infections

Interventions

  • Oral VH4524184Drug

    VH4524184 to be taken orally.

  • VH4524184 Formulation A SCDrug

    VH4524184 LAI Formulation A administered subcutaneously.

  • Placebo Formulation A SCDrug

    Placebo Formulation A administered subcutaneously.

  • rHuPH20Drug

    rHuPH20 administered subcutaneously.

  • VH4524184 Formulation B SCDrug

    VH4524184 LAI Formulation B administered subcutaneously.

  • Placebo Formulation B SCDrug

    Placebo Formulation B administered subcutaneously.

  • VH4524184 Formulation A IMDrug

    VH4524184 LAI Formulation A administered intramuscularly.

  • Placebo Formulation A IMDrug

    Placebo Formulation A administered intramuscularly.

  • VH4524184 Formulation B IMDrug

    VH4524184 LAI Formulation B administered intramuscularly.

  • Placebo Formulation B IMDrug

    Placebo Formulation B administered intramuscularly.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants reporting adverse events (AEs) and related AEsTime frame: From first study dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
  2. Percentage of participants with AEs by severityTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
  3. Percentage of participants discontinuing the treatment due to AEsTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
  4. Change from baseline in alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase parametersTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
  5. Change from baseline in total bilirubin parametersTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
  6. Change from baseline in international normalized ratio (INR) parametersTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
  7. Maximum toxicity grade increase from baseline in ALT, AST and alkaline phosphataseTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
  8. Maximum toxicity grade increase from baseline in total bilirubinTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
  9. Maximum toxicity grade increase from baseline in INRTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
  10. Percentage of participants reporting injection site reaction (ISR) AEsTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
  11. Duration of injection site reaction AEsTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
  12. Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinity time (AUC[0-inf]) of LAI VH4524184 following single dose administrationTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
  13. Area under the plasma drug concentration-time curve from zero (pre-dose) to the end of the dosing interval at steady state (AUC[0-t]) of LAI VH4524184 following multiple dose administrationTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
  14. Maximum observed plasma drug concentration (Cmax) of LAI VH4524184 following single dose administrationTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
  15. Cmax of LAI VH4524184 following multiple dose administrationTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
  16. Time to maximum observed plasma drug concentration (Tmax) of LAI VH4524184 following single dose administrationTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
  17. Tmax of LAI VH4524184 following multiple dose administrationTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
  18. Apparent terminal half-life (t1/2) of LAI VH4524184 following single dose administrationTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants
  19. t1/2 of LAI VH4524184 following multiple dose administrationTime frame: From first dose administration (Day 1) up to Week 52 post last dose, and Week 80 post last dose for a sub-group of participants

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Lenexa, Kansas · Recruiting

  • GSK Investigational Site

    Las Vegas, Nevada · Recruiting

  • GSK Investigational Site

    Austin, Texas · Recruiting

  • GSK Investigational Site

    San Antonio, Texas · Recruiting

  • GSK Investigational Site

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.